; for the ESO-KSU session participants* Abstract About the meeting: The purpose of the European Stroke Organisation (ESO)-Karolinska Stroke Update Conference is to provide updates on recent stroke therapy research and to give an opportunity for the participants to discuss how these results may be implemented into clinical routine. Several scientific sessions discussed in the meeting and each session produced consensus statements. The meeting started 20 years ago as Karolinska Stroke Update, but since 2014, it is a joint conference with ESO. Importantly, it provides a platform for discussion on the ESO guidelines process and on recommendations to the ESO guidelines committee on specific topics. By this, it adds a direct influence from stroke professionals otherwise not involved in committees and work groups on the guidelines procedure. The discussions at the conference may also inspire new guidelines when motivated. The topics raised at the meeting are selected by the scientific programme committee mainly based on recent important scientific publications. The ESO-Karolinska Stroke Update consensus statement and recommendations will be published every 2 years and it will work as implementation of ESO-guidelines Background: This year's ESO-Karolinska Stroke Update Meeting was held in Stockholm on 13-15 November 2016. There were 10 scientific sessions discussed in the meeting and each session produced a consensus statement (Full version with background, issues, conclusions and references are published as web-material and at http://www.eso-karolinska.org/2016 and http://eso-stroke.org) and recommendations which were prepared by a writing committee consisting of session chair(s), secretary and speakers and presented to the 312 participants of the meeting. In the open meeting, general participants commented on the consensus statement and recommendations and the final document were adjusted based on the discussion from the general participants. Recommendations (grade of evidence) were graded according to the 1998 Karolinska Stroke Update meeting with regard to the strength of evidence. Grade A Evidence: Strong support from randomised controlled trials and statistical reviews (at least one randomised controlled trial plus one statistical review). Grade B Evidence: Support from randomised controlled trials and statistical reviews (one randomised controlled trial or one statistical review). Grade C Evidence: No reasonable support from randomised controlled trials, recommendations based on small randomised and/or non-randomised controlled trials evidence.
Contrast enhanced magnetic resonance imaging (MRI) angiography (MRA) and MRI with T1-fat suppression sequences is the recommended imaging modality to diagnose extra-and intracranial CAD. When not available computed tomography (CT) and CT angiography (CTA) might be alternatives grade C.
2. Acute stroke in the setting of CAD: Is thrombolysis safe?
Acute ischaemic stroke (AIS) patients with suspected or confirmed extracranial CAD should not be excluded from intravenous or intra-arterial thrombolysis or mechanical thrombectomy (grade C).
Should we use anticoagulants or antiplatelet drugs to prevent CAD?
For extracranial CAD:
a. Antithrombotic treatment is strongly recommended (Grade C). b. There is no evidence of any difference between antiplatelets and anticoagulants (heparin followed by warfarin) (Grade B).
For intracranial dissection in the absence of SAH, antiplatelet drugs are recommended (Grade C).
Is there a role for angioplasty and stenting?
Angioplasty and stenting may be considered in CAD patients with recurrent ischaemic symptoms despite antithrombotic treatment (Grade C).
What is the optimal duration of medical treatment?
Antithrombotic treatment is recommended for at least 6-12 months. In patients in whom full recanalisation of the dissected artery has occurred and there have been no recurrent symptoms stopping antithrombotic treatment may be considered. In case of a residual dissecting aneurysm or stenosis, long-term antiplatelet treatment is recommended (Grade C). Patients with atrial fibrillation and AIS-timing of anticoagulation 1. When is the best time for initiating anticoagulation treatment after AIS based on RAF study?
In patients with AIS and atrial fibrillation, we recommend that oral anticoagulation treatment may be started at day 4 in mild stroke and small infarct, at day 7 in moderate stroke with medium infarcts, and at day 14 in severe stroke with large infarcts from index stroke. More data from randomised controlled trials (RCTs) and prospective registries are needed to verify these time-points, in particular for direct oral anticoagulants (Grade C).
2. Should low molecular weight heparin (LMWH) not be used alone or prior to start of oral anticoagulation treatment in patients with AF and ischaemic stroke?
Based on observational study results, bridging therapy with LMWH, prior to oral anticoagulation therapy may not be used in patients with atrial fibrillation and ischaemic stroke (Grade C).
Prevention of stroke in patients with patent foramen ovale (PFO): An update 1. Are there sufficient data from the available RCTs to recommend device closure of a symptomatic (Stroke/TIA) PFO? To whom?
We recommend that percutaneous PFO closure should be offered to patients with cryptogenic stroke and a PFO provided that the PFO is likely stroke-related according to the RoPE score (Grade A).
2. Considering the best medical treatment-antiplatelets vs. anticoagulation. Long-term follow-up with no crossover and loss of follow-up in the studies is a serious concern. Are further studies feasible?
Current evidence did not show any difference in outcome comparing oral anticoagulation and antiplatelet therapy for secondary stroke prevention in patients with PFO. We recommend future randomized trials comparing different antithrombotic/anticoagulant approaches in patients with cryptogenic stroke and PFO, especially trials that include the non-vitamin K antagonist (VKA) oral anticoagulants (Grade B).
3. Is the RoPE score good enough to differentiate between 'incidental' and 'causal' PFO?
Currently, the Risk of Paradoxical Embolism (RoPE) score represents the best tool to estimate the probability whether a discovered PFO is likely stroke-related or incidental. It is desirable that the ROPE score be validated in a prospective large cohort (Grade B).
Update on carotid surgery and stenting 1. Given the recent improvements in medical therapy, should we continue to base our treatment decisions on data from 'old' symptomatic carotid trials?
Patients with symptomatic carotid stenosis and a high risk of recurrent stroke (e.g. >70% carotid stenosis, ischaemic event <2 weeks previously) should be offered timely intervention with carotid intervention (Grade A).
Patients with symptomatic carotid stenosis and lower-risk of recurrent stroke (e.g. moderate carotid stenosis, retinal symptoms only, event > 2 weeks previously) may be randomised to trials comparing carotid intervention plus medical therapy vs. medical therapy alone (ECST-2/CREST-2) if clinician and patient substantially uncertain about the benefits of intervention (Grade B).
2. Is it ever appropriate to intervene on a <50% symptomatic stenosis?
Almost all patients with <50% symptomatic carotid stenosis should not be treated with intervention. However, intervention in certain patients may be considered if the stenosis causes recurrent symptoms despite optimal medical therapy (Grade C).
3. Does gender matter -Do women really derive less benefit from carotid intervention than men?
Decisions on whether or not to intervene on patients with carotid stenosis should not be based on gender (Grade A).
4. With more experience, better case selection and technological advances, can CAS compete with carotid endarterectomy?
Carotid artery stenting (CAS) is an effective alternative intervention in selected cases (e.g. not recently symptomatic, age <70 years, no prior ischaemic brain damage) when done by experienced interventionists. Technological advances in cerebral protection, access and stent design should be considered in patients treated with CAS (Grade A).
Session 3: Lipid lowering for primary and secondary stroke preventionNew guideline?
Chair: E. Berge (Oslo), Secretary: T. Prazeres Moreira (Stockholm), Speakers: G. Ntaios (Larissa) and A. Charidimou (London)
1. Should aggressive lipid lowering therapy be given for secondary prevention of stroke?
We recommend that statins be used as a part of standard secondary prophylactic treatment after an ischaemic stroke or a transient ischaemic attack (TIA). Benefits were observed both with atorvastatin 80 mg and with simvastatin 40 mg (Grade A). The use of statins in secondary prevention of ischaemic stroke caused by less frequent non-atherosclerotic etiologies such as arterial dissection and PFO requires further investigations.
2. Should lipid lowering therapy be given in the acute phase of stroke?
There is no evidence from RCTs to support the routine use of statins in the acute phase of stroke (first 2 weeks). However, observational studies do not show an increase in symptomatic ICH in patients previously treated with statins or to whom statin was given within 3 days after stroke. Statin treatment is thus recommended to start before discharge from hospital after an AIS or at least during follow-up (Grade C).
Should statins be used after intracerebral haemorrhage (ICH)?
Statins should be used with caution in patients with previous spontaneous ICH (Grade C) -changed from previous KSU recommendation. Avoiding high-dose statin regimens in patients with ICH should be considered (Grade A) -new. In a subgroup of patients with cerebral amyloid angiopathy-related lobar ICH, statin use should probably be reserved for compelling indications (Grade C). 3. For patients with a suspected LAO based on current clinical tools on field, there is uncertainty about the equipoise between drip and ship (that prioritizes early IVT and other standard of care therapies) and mother-ship (that prioritizes early endovascular thrombectomy) models. Data based on randomized controlled trials are needed to determine the most beneficial model for each particular patient (eligible or not for iv-tPA) in different geographical regions and to establish isochrones where a particular model may be beneficial (Grade C). 4. In the absence of evidence, for patients considered eligible to IVT in the field, if estimated transfer time to the nearest primary stroke centre is considerably shorter than time to a comprehensive stroke centre (approximately more than 30-45 min), the drip and ship model should be considered (Grade C). 5. In the absence of evidence, in a scenario where a primary stroke centre and comprehensive stroke centre are equidistant (approximately not more than 30-45 min apart) or when contraindications to IVT are known in the field, patients with suspected LAO in the field, should be considered for transfer directly to a comprehensive stroke centre, bypassing any closer primary stroke centres (Grade C). 6. In case of primary admission to a primary stroke centre, evaluation and treatment for patients with a possible LAO must be expeditious, to ensure a rapid secondary transfer to a comprehensive stroke centre, avoiding any sources of delay such as complex neuroimaging studies (i.e. perfusion studies) or waiting for effect of IVT. First picture to puncture time should be less than 90 min (Grade A).
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